Article Figures & Data
Figures
- FIGURE 1.
Graph showing number of deaths in various years. Of female patients, 3 died after 2008.
- FIGURE 2.
Life-span curves showing clear sex difference, but with log-rank test giving P value of 0.195.
- FIGURE 3.
Kaplan–Meier curves clearly indicating that patients who showed cumulative disease control (complete response [CR] + partial response [PR] + minor response [MR] + stable disease [SD]) after initial PRRT regime had significantly better overall survival than did patients with progressive disease (PD) (P < 0.001, log rank).
- FIGURE 4.
Graph showing that only 18% of patients initially treated with 90Y-therapy were alive after 12 y, whereas nearly 48% of patients in 177Lu group were alive.
Tables
- TABLE 1
Age of Deceased Patients at Date of Death or of Survivors on Final Date of Evaluation
Sex Life status n Mean SD Minimum Maximum Female Alive 8 55.4 6.2 47 64 Dead 9 62.1 13.2 41 78 Male Alive 6 56.2 6.4 47 62 Dead 21 62.0 12.7 40 84 All Alive 14 55.7 6.0 47 64 Dead 30 62.0 12.6 40 84 Both 44 60.0 11.3 40 84 Primary tumor Alive (n) Dead (n) Alive (%) Mean age at diagnosis (y) Median survival (mo) NET of pancreas 4 12 25.0 59.3 (SD, 11.9) 42 (95% CI, 23–107) NET of small bowel 6 9 40.0 58.1 (SD, 10.6) 125 (95% CI, 30–NA) NET unknown primary 2 2 50.0 59.8 (SD, 10.4) NA (95% CI, 75–NA) NET of lung 1 3 25.0 65.8 (SD, 5.9) 49 (95% CI, 8–NA) NET of rectum 1 2 33.3 67.0 (SD, 17.0) 115 (95% CI, 20–NA) Reticulum sarcoma, glomus tumor 0 2 0.0 58.5 (SD, 20.5) 51.0 (95% CI, 23–79) No. of systems Alive (n) Dead (n) Alive (%) Mean age at diagnosis (y) Median survival (mo) 1 5 7 41.7 60.8 (SD, 9.4) 97 (95% CI, 23–NA) 2 6 15 28.6 60.0 (SD, 10.6) 81 (95% CI, 41–127) 3, 4 3 8 27.3 59.3 (SD, 14.8) 23 (95% CI, 18–NA) NA = not applicable.
Response to therapy Alive (n) Dead (n) Alive (%) Mean age at diagnosis (y) Median survival (mo) Partial or complete response 3 7 30.0 65.6 (SD, 10.7) 86 (95% CI, 23–NA) Stable disease or minor response 11 14 44.0 57.2 (SD, 10.2) 125 (95% CI, 79–NA) Progressive disease 0 9 0.0 61.6 (SD, 13.2) 25 (95% CI, 16–46) NA = not applicable.
Jump to section
Related Articles
Cited By...
- The Future of Health Care and the Importance of the Nuclear Medicine Technologist
- Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy
- Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer